相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period
Atsushi Ogata et al.
MODERN RHEUMATOLOGY (2018)
Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial
Christopher J. Edwards et al.
RHEUMATOLOGY (2018)
Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies
Xavier M. Teitsma et al.
RHEUMATOLOGY (2018)
A review of sarilumab for the treatment of rheumatoid arthritis
Eun Bong Lee
IMMUNOTHERAPY (2018)
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab
Cesar Diaz-Torne et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA
F. Iannone et al.
CLINICAL RHEUMATOLOGY (2018)
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
Mari Kihara et al.
CLINICAL RHEUMATOLOGY (2017)
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in PatientsWith Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
Hisham Abdallah et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
Robert J. Moots et al.
RHEUMATOLOGY (2017)
Effects of tocilizumab on neutrophil function and kinetics
Laurence S. C. Lok et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2017)
Sirukumab: a promising therapy for rheumatoid arthritis
Eleftherios Pelechas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Safety profile of biological therapies for treating rheumatoid arthritis
Juan D. Canete et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation
Le-Feng Chen et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2017)
Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
Carmen Garcia-Gomez et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
The role of IL-6 in host defence against infections: immunobiology and clinical implications
Stefan Rose-John et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
Jacques Morel et al.
RHEUMATOLOGY (2017)
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice A Nationwide Cohort Study From Sweden
Hjalmar Wadstroem et al.
JAMA INTERNAL MEDICINE (2017)
Transaminase Levels and Hepatic Events During Tocilizumab Treatment Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study
Seoyoung C. Kim et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
Vibeke Strand et al.
RMD OPEN (2017)
Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
Rene-Marc Flipo et al.
RMD OPEN (2017)
CLINICAL REMISSION IN SUBJECTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE OR OTHER SYNTHETIC DMARDS: A REALWORLD CLINICAL TRIAL (TOSPACE)
R. Sanmarti et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Martin Soubrier et al.
RHEUMATOLOGY AND THERAPY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis
Yunwei Li et al.
ATHEROSCLEROSIS (2017)
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany
Christof Iking-Konert et al.
RHEUMATOLOGY (2016)
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
Carina Gotestam Skorpen et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
Yuko Kaneko et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study
A. Gardette et al.
CLINICAL RHEUMATOLOGY (2016)
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
Johannes W. J. Bijlsma et al.
LANCET (2016)
Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review
Emilio Martin-Mola et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data
Maria Hoeltzenbein et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
Jianmei Wang et al.
ARTHRITIS CARE & RESEARCH (2016)
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
Fenglong Xie et al.
ARTHRITIS & RHEUMATOLOGY (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
Andrea Rubbert-Roth et al.
RMD OPEN (2016)
SMOKING STATUS DOES NOT SEEM TO AFFECT TOCILIZUMAB EFFICACY IN RA PATIENTS
E. Theander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice
Marina Backhaus et al.
CLINICAL RHEUMATOLOGY (2015)
Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient
Yves-Marie Pers et al.
JOURNAL OF RHEUMATOLOGY (2015)
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry
Cem Gabay et al.
RHEUMATOLOGY (2015)
Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study
Alejandro Balsa et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Vijay U. Rao et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)
Clifton O. Bingham et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
T. W. J. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Therapeutic uses of anti-interleukin-6 receptor antibody
Sujin Kang et al.
INTERNATIONAL IMMUNOLOGY (2015)
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study
Toshihisa Kojima et al.
RHEUMATOLOGY (2015)
2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis
Raimon Sanmarti et al.
REUMATOLOGIA CLINICA (2015)
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases
Hiroshi Fujiwara et al.
Modern Rheumatology (2014)
Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis
Christian Enevold et al.
PHARMACOGENETICS AND GENOMICS (2014)
Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
Helen L. Wright et al.
RHEUMATOLOGY (2014)
Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Alan Kivitz et al.
ARTHRITIS CARE & RESEARCH (2014)
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Atsushi Ogata et al.
ARTHRITIS CARE & RESEARCH (2014)
Tocilizumab in the treatment of rheumatoid arthritis and beyond
Anjali Shetty et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome-Wide DNA Microarray
Yoshie Sanayama et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Rheumatoid Arthritis: A Clinical Overview of New Diagnostic and Treatment Approaches
Raimon Sanmarti et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Exposure-Exposure Relationship of Tocilizumab, an AntiIL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis
Micha Levi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study
Michael E. Weinblatt et al.
ARTHRITIS CARE & RESEARCH (2013)
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
Yusuf Yazici et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
Vivian P. Bykerk et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
Vibeke Strand et al.
RHEUMATOLOGY (2012)
Pathways for Bone Loss in Inflammatory Disease
Tobias Braun et al.
CURRENT OSTEOPOROSIS REPORTS (2012)
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Moetaza M. Soliman et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review
Jasvinder A. Singh et al.
JOURNAL OF RHEUMATOLOGY (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
Gert J. D. Bergman et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srinivasan Srirangan et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study
Susan J. Lee et al.
JOURNAL OF RHEUMATOLOGY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Paul Emery et al.
LANCET (2008)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
分享论文
